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Simple Summary: Primary bone cancers like osteosarcoma (OS) are driven by bone cells that
develop mutations, and behave in an uncontrolled manner. All bone cells, including defective
ones, are sensitive to their physical environment. We tested the response of osteosarcoma cells,
at the gene level, to two different kinds of mechanical stimulus, which are relevant to the tumor
microenvironment. The first was fluid flowing over their surface, and the second was stiffness or
rigidity of the surface beneath. In our study we found that fluid flow in particular has the ability to
change the behavior of OS cancer cells, and could potentially be used to reduce their harmful effects.
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Abstract: Osteosarcoma (OS) is an aggressive bone cancer originating in the mesenchymal lineage.
Prognosis for metastatic disease is poor, with a mortality rate of approximately 40%; OS is an
aggressive disease for which new treatments are needed. All bone cells are sensitive to their mechanical/physical surroundings and changes in these surroundings can affect their behavior. However, it is
not well understood how OS cells specifically respond to fluid movement, or substrate stiffness—two
stimuli of relevance in the tumor microenvironment. We used cells from spontaneous OS tumors
in a mouse engineered to have a bone-specific knockout of pRb-1 and p53 in the osteoblast lineage.
We silenced Sox2 (which regulates YAP) and tested the effect of fluid flow shear stress (FFSS) and
substrate stiffness on YAP expression/activity—which was significantly reduced by loss of Sox2, but
that effect was reversed by FFSS but not by substrate stiffness. Osteogenic gene expression was also
reduced in the absence of Sox2 but again this was reversed by FFSS and remained largely unaffected
by substrate stiffness. Thus we described the effect of two distinct stimuli on the mechanosensory
and osteogenic profiles of OS cells. Taken together, these data suggest that modulation of fluid
movement through, or stiffness levels within, OS tumors could represent a novel consideration in the
development of new treatments to prevent their progression.
Keywords: osteosarcoma; mechanobiology; osteogenesis; shear stress; substrate stiffness
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1. Introduction
Osteosarcoma (OS) is an aggressive bone cancer that originates in the osteoblast
lineage and is the most common primary bone malignancy worldwide. OS tumors normally
develop during growth phases in children, adolescents and young adults [1]. Typically,
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OS develops as a solid tumor which forms at the metaphyseal growth plate of long bones
in the appendicular skeleton. The most common sites are in the distal femur, proximal
tibia and humerus [2]. The annual occurrence rate of OS is less than 10 per million in the
USA. However, at the time of diagnosis, tumors tend to be advanced. OS also has a high
rate of metastasis, and 90% of metastases are found in the lungs [1]. Thus, prognosis for
metastatic disease is generally poor, and with a mortality rate of approximately 40%, OS is
an extremely aggressive disease for which new treatments are needed [3,4].
The early stage of any cancerous development is difficult to define precisely. However,
it appears that the pathological processes of OS start when multipotent mesenchymal
stem cells (MSCs) in bone marrow lose their ability to successfully complete osteogenic
differentiation. This can be due to multiple mutations in regulatory pathways such as p53
and retinoblastoma (Rb), and OS tumors are common in patients with hereditary mutations
in these genes [5]. Confirming the involvement of these genes in the development of OS,
mice with conditional deletions in Rb and p53 develop spontaneous OS tumors. At this
stage, some of these cells are termed OS cancer stem cells (CSCs), and can be identified
by expression of the stem cell marker Sca-1 [6]. CSCs are thought to be a self-renewing
population of cells that maintain tumor development. These CSCs then form a small
but persistent subpopulation of undifferentiated cells [7]. CSCs are notoriously difficult
to locate, identify and target/remove. For this reason, they are strongly implicated in
disease relapse since they can persist, even following treatments/surgery, in self-renewing
reservoirs [8]. Once this group is established, a period of rapid cell proliferation occurs
during which a second distinct pathological subpopulation emerges [9]. Pre-osteoblasts,
stuck in the early stages of differentiation, produce excessive amounts of disorganized
extracellular bone matrix (osteoid). This tissue is what eventually comes to make up
the bulk of the OS tumor mass. The CSC population plays a central role in driving the
uncontrolled growth and activity of the pre-osteoblastic subpopulation of tumor cells, and
several molecular mechanisms such as oncogene activation and tumor suppressor loss
have been linked to their dysregulation [10]. Although OS CSCs can be difficult to locate
and characterize, one identifiable trait is constitutively high expression of an oncogene
called Yes-Associated Protein (YAP) [11].
YAP is a potent growth promoter involved in healthy growth and development of
many tissues, including bone [12], but is also reactivated and heavily involved in skeletal tumorigenicity. YAP activity is kept in check by the tumor suppressive Hippo pathway [13,14].
YAP activity is also controlled, at a transcriptional level, by Sox2, which is well known for
its role in maintaining stemness. Sox2 is one of a suite of genes that regulate the osteoblast
lineage from its multipotent MSC lineage, and thus also has a role in cancers that originate
from dysregulation in this lineage [15]. An important mechanism that links Sox2 activity
with CSCs is its role in regulating the tumor suppressive Hippo pathway [15]. Specifically,
Sox2 represses two Hippo activators, Nf2 and WWC1, thereby leading to YAP stabilization downstream and its ability to effect transcription of YAP target genes in the nucleus.
Thus, inhibition of Sox2 can increase Hippo activity and restrain YAP by phosphorylation
and nuclear exclusion and thus reduce tumorigenicity [16,17]. YAP is potently oncogenic
in several tumor types [11,13,17] and we have found that YAP is overexpressed in several mouse and human OS cells lines where its nuclear expression marks a population
of Sca-1High multipotent CSCs [18]. YAP ablation in mouse OS cells restores osteoblast
differentiation, reduces tumorigenicity and sensitizes cells to chemotherapy, suggesting
that YAP expression is heavily involved in maintaining CSCs in OS [19]. In line with these
findings, agents that lead to differentiation of OS CSCs cause cytoplasmic sequestration of
YAP and decreased expression of its target genes [10].
Intriguingly, YAP has also been shown to be a highly mechanosensitive factor [20,21].
This is relevant for two reasons. Firstly, bone cells are well known to be highly sensitive
to shear stresses created by localized interstitial fluid movements [22]. Solid tumor development has been shown to cause differential localized fluid movements, and increased
interstitial pressure within the tissue [23,24]. This leads to differential fluid flow shear
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stresses (FFSS) throughout the tumor mass, and its local microenvironment [25,26]. Secondly, at the local tissue level, rapid and poorly controlled tumor growth results in a highly
heterogeneous tissue microenvironment at the material level [27]. Native healthy bone
alongside increasing amounts of poorly organized osteoid tissue form a heterogeneous
and disparate substrate for tumor cell populations. Thus, knowledge of how OS cells behave in environments with differing physical/mechanical properties (e.g., FFSS/substrate
stiffness), representative of the tumor microenvironment, is an important aspect of understanding disease development and progression. Our goal was to determine the effect
of FFSS, and substrate stiffness on tumorigenic and osteogenic characteristics of OS cells.
Specifically, we isolated primary murine OS cells, and used these two stimuli to modulate
YAP activity (via Sox2) and osteogenic differentiation via bone-specific genes.
2. Materials and Methods
2.1. Isolation, Transfection and Sox2 Knockdown in mOS482 Cells
Primary osteosarcoma cells (mOS482), isolated from spontaneous OS tumors occurring in a mouse model that was engineered to have a bone-specific knockout of pRb-1
and p53, and two tumor-suppressive genes in the osteoblast lineage have been previously described [18]. Qualitative histological evaluation of the tumor mass, on standard
formalin fixed paraffin embedded (FFPE) samples, was also carried out to assess tumor
tissue composition and structure. In order to study the role of Sox2 and YAP, and the
relationship between the two in tumorigenesis and osteoblast function, msOS482 cells
were transduced with either non-targeting scrambled short hairpin RNA (Scr) or targeted
shRNA for Sox2 (shSox2) using retroviral transfection. Standard immunocytochemistry
(ICC) methods were used to evaluate transfection efficiency. Briefly, cells were washed,
fixed (4% paraformaldehyde at 37 ◦ C) and permeabilized (0.1% Triton X-100) in PBS, and
further blocked for 30 min with 2% BSA/PBS. Then, cells were incubated with a primary
polyclonal antibody against Sox2 (48–1400, Thermo Fisher, Branchburg, NJ, USA) in 1:200
dilution for 1 h. After two washes with PBS, cells were incubated with secondary antibody
at 1:200 (A11034, Alexa Fluor® 488, Thermo Fisher, Branchburg, NJ, USA), phalloidin
(A22283, Alexa Fluor® 546, Thermo Fisher, Branchburg, NJ, USA) at 1:500 dilution, and
DAPI (P36935, Thermo Fisher, Branchburg, NJ, USA) for nuclear staining. Finally, imaging
was carried out with a Nikon Ti-Eclipse (Nikon, Japan) microscope at 40X magnification.
2.2. Fluid Flow Shear Stress (FFSS)
For FFSS studies, mOS482 cells were plated on collagen type I coated microscope slides
at a density of 1 × 105 cells/slide and cultured in high-glucose MEM media (Sigma Aldrich,
Carlsbad, CA, USA) for 24 h. Cells were then placed in a commercial fluid flow system
(Flexcell Corp. Int., Burlington, NC, USA), which subjected them to a continuous laminar
fluid flow regime, at a calculated shear stress level (at cell surface) of 1 kPa. We, and others,
have previously found this to be a physiologically relevant mechano-stimulatory shear
stress level [28]. The system was maintained in high-glucose MEM media with standard
penicillin/streptomycin (Sigma Aldrich, Carlsbad, CA, USA) for 2 h. The cells were also
treated with hygromycin (Sigma Aldrich, Carlsbad, CA, USA) in all experiments to ensure
retention of vector cargo. Control cells were plated on slides and maintained in the same
media and conditions but not subjected to flow. Cells were then collected and processed for
subsequent analyses. Firstly, the intracellular location of YAP was determined using ICC
and image analyses. ICC was carried out as described above—cells were washed, fixed
and permeabilized, and then blocked with 2% BSA/PBS. Cells were then incubated with a
primary monoclonal mouse antibody against YAP-1 (10413M1, Sigma Aldrich, Carlsbad,
CA USA) in 1:400 dilution for 1 h. After two washes with PBS, cells were incubated for 1
h with goat-anti-mouse secondary antibody at 1:200 (20691, Thermo Fisher, Branchburg,
NJ, USA) and then imaged as before. Then, to assess its activity as well as location,
gene expression of direct downstream targets of YAP (cysteine-rich angiogenic inducer 61
(CYR61)), connective tissue growth factor (CTGF), and brain-derived neurotrophic factors

Cancers 2021, 13, 3128

4 of 12

(BDNF)) were also measured using standard qPCR methods. To assess the osteogenic status
of the cells in each experimental group, standard gene expression studies were also carried
out to assess runx2, osterix, osteocalcin and osteoprotegrin (OPG) levels. For these, and
all subsequent qPCR procedures in this study, total RNA was extracted using the RNeasy
mini kit (Qiagen, CA, USA) and treated with DNase following manufacturer protocols.
Then, 0.5 µg of purified RNA was reverse transcribed at 42 ◦ C for 65 min using SuperScript
II RT and Oligo(dT) as a primer in a final volume of 20 µL and 2 µL of sample was used as
a template for amplification using gene-specific primers sets. RT-PCR was carried out on a
Light Cycler Instrument using the DNA Master SYBR Green I dye intercalation assay with
B-actin used as a normalization control.
2.3. Polyacrylamide (PA) Substrate Fabrication and Mechanical Testing
Polyacrylamide (PA) hydrogels were used in these studies as substrates with easily
modifiable stiffness. Stiffness levels of approximately 1 and 60 kPa were used as representative ‘soft’ and ‘stiff’ substrates, respectively. These values were chosen to reflect
physiological stiffness levels at either end of the ECM tissue spectrum in OS [6]. Furthermore, these values have also been used in other studies to represent similar disparities
in tissue stiffnesses [20]. Briefly, hydrogel fabrication was carried out by coating sterilized glass slides with 0.4 mL of 0.1 M NaOH; and glass coverslips first with 0.2 mL of
3-aminopropyltrimethoxysilane (3-APTMS) and then with 1 ml of 0.5% glutaraldehyde.
At each stage, incubation/rinsing was carried out as appropriate. Ammonium persulfate,
40% acrylamide and 2% bis-acrylamide were sterilized through 0.2 µm filters. Acrylamide,
bisacrylamide, TEMED and PBS were combined to achieve the intended stiffness. Hydrogel
solution was delivered onto treated coverslips, then a second coverslip, treated with SurfaSil to siliconize the glass surface, was used to cover the construct which was then allowed
to polymerize. For crosslinking, Sulfo-SANPAH was delivered to each hydrogel and cured
using UV light (at 320–365 nm) for 10 min. Hydrogels were rinsed and 0.1 mg/mL collagen
in HEPES was applied to each hydrogel before overnight incubation. Hydrogels were then
maintained for 3 days to allow for swelling to occur and equilibrium to be reached. For
mechanical analysis cylindrical hydrogel samples (15 mm diameter; 5 mm height) were
formed using standard molds. Mechanical testing was performed using a Bose Electroforce
3200 with impermeable circular platens. Samples were secured between platens and tested
in compression under displacement control at a rate of 0.001 m/sec and stiffness values
were calculated at 10% strain [29]. System-based WinTest software was used to record test
data which was then exported to a custom Matlab script for processing and analyses.
2.4. Cell Culture on PA Substrates
Cell culture studies on PA substrates were carried out in standard conditions, as
described above, for 10 days using supplemented MEM media. Hydrogels were fabricated
and treated as before. Firstly, the effect of substrate stiffness on mOS482 cell proliferation
was determined. Using a standard CCK-8 absorbance assay, cell growth on each substrate
was measured using a hemocytometer every 24 h. Then ICC was used as before to measure
the intracellular location of YAP. Cells from each substrate group were fixed, permeabilized
and incubated with a monoclonal mouse antibody against YAP (and goat-anti-mouse
secondary) in BSA solution as described above. In order to assess the activity of the YAP
protein, in addition to its location, as before, gene expression of downstream targets was
measured via qRT-PCR of its direct downstream targets (CYR61, CTGF and BDNF), in
order to assess tumorigenic activity. Finally, osteogenic activity was assessed by gene
expression of the same suite of bone-specific cells as described above (i.e., runx2, osterix,
osteocalcin and OPG).
2.5. Statistical Analyses
Data are expressed as mean ± standard deviation (SD) of results from independent
experiments. Where the assumption of normally distribute data was met, the unpaired two-
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Osteogenic gene expression was also increased with FFSS, an effect that was more
pronounced in shSox2 cells with decreased Sox2 levels. Runx2 expression appeared unchanged by decrease in Sox2 in the shSox2 cells compared to control cells (scr) but was
increased by FFSS in both groups (Figure 3A), while osterix and osteocalcin expression
was significantly increased by FFSS only in the shSox2 cells (Figure 3B,C). In contrast, OPG
expression increased with FFSS in scr cells, but not in shSox2 cells (Figure 3D).
3.3. Substrate Stiffness Studies
Polyacrylamide (PA) hydrogels were reproducibly fabricated and characterized for
these studies (Figure 4A). Stiffness values of 1 and 60 kPa, for ‘soft’ and ‘stiff’ groups
respectively were chosen to represent relevant OS tissue properties. Mechanical testing,
following equilibration (Figure 4B), confirmed these average values in our two groups
(Figure 4C). Next, the effect of substrate stiffness on cell proliferation showed that increased
stiffness resulted in increased cell proliferation in scr cells, but this effect was diminished
in the absence of Sox2 (Figure 4D). Then, the levels of nuclear expression and cytoplasmic
expression of YAP were determined on soft and stiff substrates. These data showed that
nuclear YAP expression was not appreciably changed by stiffness, but that downregulation
of Sox2 reduced levels of nuclear YAP on soft substrates (Figure 5A). The expression levels
of downstream targets of YAP (CYR61, CTGF and BDNF) were assessed to determine its
intracellular activity, in addition to location, which was unchanged by substrate stiffness in
both cell groups (Figure 5C). Runx2 gene expression increased with stiffness in cells with
shSox2 (Figure 6A) while expression of osterix and osteocalcin decreased slightly in both
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4. Discussion
Osteosarcoma (OS) tumors account for 20% of all bone tumors and approximately
5% of all pediatric tumors, and are a highly metastatic form of malignancy. The treatment
options for OS are usually surgical resection, and/or either high-dose methotrexate, doxorubicin or cisplatin—these options have not changed in more than 4 decades and 5-year
survival rates remain between 20% and 30% for advanced disease. The cell type at the
center of this pathology is the bone marrow-derived mesenchymal stem cell (MSC). A
malfunction/mutation in genes such as p53 or Rb, which are central to cell-cycle regulation, leads to genomic instability and converts them to CSCs, that maintain stemness
features and prevent proper differentiation from occurring in these cells. Once a population
becomes established, it drives proliferation and activity of pre-osteoblastic cells—which
ultimately proceed to form tumor masses. These OS cells have high expression of the
transcriptional regulators Sox2 and Yes-Associated Protein 1 (YAP). Intriguingly, YAP
(along with its paralogue TAZ) have recently been found to have a key role in many aspects
of bone development, homeostasis and repair [30,31]. These transcription factors, and
other upstream components of the Hippo pathway that regulate their activity, have also
been directly linked with osteosarcoma [31,32]. Furthermore, these factors have also been
shown to be sensitive to their physical/mechanical environments—however, whether and
how this affects cell fate or disease progression remains unknown.
Previous work has shown that Sox2 marks and maintains cancer stem cells in a variety
of cancers, including tumors of epithelial, neural and mesenchymal origin. This reflects not
only their stem-like nature, since other stem cell transcription factors (for example, Oct4) are
not expressed in osteosarcoma cells. It is therefore of great importance to understand not
only how the expression of Sox2 is maintained or activated in OS, but also the mechanisms
by which its expression influences disease dynamics and progression. Our data show
we successfully knocked down Sox2 expression in cells harvested from primary murine
OS tumors. Sox2 is known to bind the YAP promoter in osteoprogenitors as well as
osteosarcoma cells, and can increase YAP activity in those cell types. Accordingly, we
found that the expression of nuclear YAP was reduced following shSox2 treatment. This
is potentially due to upregulation of Nf2 and WWC1 (both of which are crucial Hippo
pathway activators), which have been shown to increase phosphorylation and cytoplasmic
retention of YAP. However, it was intriguing to note that the application of FFSS was able
to reverse this response and significantly increase nuclear YAP following treatment, but did
not have this effect in controls. The expression levels of downstream targets of YAP (CYR61,
BDNF) were also decreased in absence of Sox2, but then increased by FFSS, which suggests
YAP’s location, as well as its activity, is influenced by this stimulus. Osteogenic gene
expression was also altered by FFSS, for cells with and without Sox2. Runx2 expression
increased in response to flow in both groups, while osterix and osteocalcin expression
increased significantly only in shSox2 cells in which Sox2 was depleted. This suggests that
FFSS can contribute to the restoration of normal osteogenesis in these cells. It may be that
the mechanism behind this process is related to the well-known role of FFSS in the terminal
differentiation of healthy osteoblasts into osteocytes in the mineralizing lacuna–canalicular
system. Here, FFSS is the most significant physical/mechanical force that the local cell
population experiences. In contrast, OPG expression increased with FFSS in the presence
of Sox2, but not in its absence. These data demonstrate that OS cells are mechanosensitive
and that mechanical signals generated by FFSS can increase the expression of osteogenic
genes, and may direct these cells back towards a normal differentiation program.
Soft substrates have been shown to prompt MSCs down an adipogenic lineage,
whereas stiffer ones result in progression towards an osteogenic one [14]. This differential effect is reflected in nuclear localization of YAP where stiffness appears to be a cue for
osteoblastic differentiation [14]. These studies highlight YAP as a mechanosensory factor
and we explored whether the same would be true in OS cells due to their similar mesenchymal origin. Previous work has shown that osteosarcoma cells exposed to increased levels
of stress can develop CSC characteristics, as compared to colon (25 kPa) and breast (5 kPa)
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cancer cells. This suggests that the organ of origin is a significant influence on the intrinsic
mechanosensory characteristics of a given type of tumor cell. There is accumulating evidence that the transcriptional coactivators YAP and WWTR1(TAZ) that are downstream of
the Hippo signaling pathway are exquisitely sensitive to substrate stiffness, and physical
stress. In line with these concepts, our data show that cell proliferation increases on stiffer
substrates in the presence of Sox2, but that this feature is lost in the shSox2 cells, indicating
the importance of the Sox2/YAP axis in the proliferative effect. Interestingly, we found
that nuclear YAP nuclear expression was significantly reduced on soft substrates in the
absence of Sox2, and appeared to increase with stiffness. The trend in the presence of Sox2,
while not significant, remained on stiff substrates. Similarly, expression of downstream
markers of YAP activity in these cells were not significantly different on either substrate,
in either cell type, but the trend suggested that YAP activity may be rescued by stiffness.
Despite this, osteogenic gene expression was altered by substrate stiffness, for cells with
and without Sox2. As was the case with FFSS, Runx2 expression increased with increasing
stiffness, but just in the absence of SOX2. In contrast to FFSS stimulus, stiffer substrates
seemed to reduce expression of osterix and osteocalcin but these changes did not reach significance. This suggests that substrate stiffness does not have the same potential to prompt
a full return to the osteogenic pathway as FFSS. In contrast to FFSS, OPG expression was
increased with stiffness in the absence of Sox2. These data reinforce the idea that OS cells
are mechanosensitive and suggest that physical stimulus generated by stiffer substrates
can alter the expression of osteogenic genes, but in a potentially less robust manner than
FFSS. In an OS tumor mass, increased stiffness could contribute to maintaining the cells
in an undifferentiated state by YAP induction. In line with this, increased stiffness has
been reported in other tumor microenvironments to stimulate pro-cancerous properties. In
line with this, pro-osteogenic genes did not appear to be affected by stiffness in our study.
A different trend was observed in the presence of flow where increased FFSS tended to
increase pro-osteogenic gene expression. It could be speculated that in a tumor setting,
FFSS effects could overcome increased YAP to induce osteogenesis. Thus, these data could
have implications for biophysical forces in tumor development and cancer progression.
Sox2, and thus YAP, serve as key regulators in MSC development in health and disease.
YAP in particular has been linked in recent years to development of primary bone cancers
(and metastases) when inappropriately activated. Thus, this transcription factor is being
viewed as a promising therapeutic target for the treatment of bone cancers. However,
no compounds directly targeting it have yet been identified. This may in part be due to
the extremely large interaction surface of YAP with TEAD, which small molecules may
find difficult to break [31]. In contrast, several small molecules binding to the YAP/TAZ
interaction surface of TEAD are already in development. Taken together, this highlights
the importance of this signaling pathway, and also expanding our understanding of how it
responds to changes in its mechanical and physical environment.
5. Conclusions
In conclusion, we have described the effect of two distinct physical stimuli (FFSS
and substrate stiffness), which are of relevance to OS tumors, on the mechanosensory
and osteogenic profiles of murine OS cells. YAP expression, which is highly sensitive
to mechanical stimulus, is also under control of Sox2, and the lack of this key regulator
significantly influenced the response to mechanical stimulus—especially FFSS. Taken
together these data suggest that modulating fluid movement through, or stiffness levels
within, OS tumors could augment their course of progression.
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